Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of
Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
On 6ix: 6ix.com/news/xenon-pharmaceuticals-presents-additional-positive-data-from-phase-2b-x-tole-clinical
Watch Xenon Pharmaceuticals' latest callXenon Pharmaceuticals (NASDAQ:XENE) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of Xenon Pharmaceuticals (NASDAQ:XENE) Q2 2026 Earnings CallXenon Pharmaceuticals' next earnings callXenon Pharmaceuticals (NASDAQ:XENE) Q3 2026 Earnings Call · Nov 9, 2026 at 4:30 PM ESTRegister
Xenon Pharmaceuticals Inc. on 6ix
Story so far
- Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101
- Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders
Earlier from Xenon Pharmaceuticals
- Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering
- Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
Later from Xenon Pharmaceuticals
- Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022
- Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
- Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
Follow Xenon Pharmaceuticals into a list and get an email when it puts out news.
Follow Xenon Pharmaceuticals